Whitehawk Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | |
| – | +50.6% | +1,066.7% | +51.4% | +6.3% | +14.2% | -59.1% | |
| – | +31.0% | +1,415.1% | +357.9% | +24.0% | -9.3% | -8.9% | |
| – | -1,130.2% | – | -227.4% | – | – | -48.2% | |
| – | -100.0% | – | +865.2% | +794.6% | -58.4% | -66.6% | |
| – | – | – | -628.3% | – | -69.7% | -52.8% | |
| – | – | – | -100.0% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | -85.2% | +11,776.4% | -48.8% | -99.6% | -60.1% | +72,496.9% | |
| – | -172.1% | – | -176.0% | – | -243.4% | – | |
| – | – | – | – | – | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.